๐ ๐๐๐ฌ๐ฎ๐ฅ๐ญ๐ฌ
โข EPS: $1.94 (Est. $1.84) โ
โข Revenue: $6.30B (Est. $6.14B) โ
โข Core revenue growth: +3.0% YoY
โข Core revenue growth ex-respiratory testing: +4.5% YoY
โข Free cash flow: $1.3B
โ
๐ฏ ๐๐ฎ๐ข๐๐๐ง๐๐
โข Q3 core revenue growth: +2.0% to +3.0% YoY
โข FY2026 core revenue growth: +3.0% to +4.0% YoY
โข FY2026 EPS: $8.45โ8.60 (Est. $8.50) ๐ฐ
โข Raised FY2026 EPS guidance from $8.35โ8.55 previously
โ
๐ ๐๐๐ฒ ๐๐๐ค๐๐๐ฐ๐๐ฒ๐ฌ
โข Revenue increased 5.5% as Life Sciences delivered its strongest quarter in several years.
โข Bioprocessing orders grew at a mid-teens rate despite customer project timing impacting reported revenue.
โข Earlier-than-expected completion of the Masimo acquisition supported the higher full-year EPS outlook.
โ
๐ฌ ๐๐๐ง๐๐ ๐๐ฆ๐๐ง๐ญ ๐๐จ๐ฆ๐ฆ๐๐ง๐ญ๐๐ซ๐ฒ
Management said continued end-market recovery and recent growth initiatives are expected to support a mid-single-digit core revenue growth exit rate for 2026. The company also highlighted its portfolio, capital deployment flexibility and the Danaher Business System as key long-term growth drivers.
